Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3
Status:
Completed
Trial end date:
2021-10-04
Target enrollment:
Participant gender:
Summary
The study should evaluate distribution of 99mTc-HE3-G3 in patients with primary HER2-positive
and HER2-negative breast cancer.
The primary objective are:
1. To assess distribution of 99mTc-HE3-G3 in normal tissues and in tumours over time;
2. To evaluate dosimetry of 99mTc-HE3-G3;
3. To obtain initial information concerning safety and tolerability of 99mTc-HE3-G3 after
single intravenous injection:
The secondary objective are:
1.To compare the tumour imaging data with the concerning HER2 expression obtained by
immunohistochemistry (IHC) or fluorescent in situ hybridisation (FISH) analysis of biopsy
samples.
Phase:
Phase 1
Details
Lead Sponsor:
Tomsk National Research Medical Center of the Russian Academy of Sciences
Collaborators:
Institute of Bioorganic Chemistry, Russian Academy of Sciences Uppsala University